Summary Recurrence and survival rates were studied in 175 women with breast cancer who, until the development of recurrent disease, received no treatment other than a modified radical (Patey) mastectomy, and in whom the oestrogen (REc) and progesterone (RPc) receptor content of the primary tumour was measured. At the time of first relapse most patients received endocrine therapy.
Several reports have suggested that early recurrence of breast cancer is clearly associated with a lack of either oestrogen receptors (REc) or progesterone receptors (RPc) in the primary tumour (Allegra et al., 1979; Cooke et al., 1979 . Forrest et al., 1980 Westerberg et al., 1980; Paterson et al., 1982; Pichon et al., 1980; Mason et al., 1983; Clark et al., 1983) . However the evidence is conflicting and data from other studies have failed to confirm the value of either REc or RPc as a guide to prognosis, (Hilf et al., 1980; Shapiro et al., 1982; Howat et al., 1983; Allegra et al., 1979; Kinne et al., 1981; Mason et al., 1983; Stewart et al., 1983) .
By contrast there is general agreement that patients with breast cancer whose tumours contain REc survive longer after mastectomy than those who do not have this receptor (Bishop et al., 1979; Hahnel et al., 1979; Croton et al., 1981; Kinne et al., 1981; Samaan et al., 1981; Von Maillot et al., 1982; Mason et al., 1983; Stewart et al., 1983) . Although there are few data on the role of RPc and survival, Mason and her colleagues (1983) reported significant improvement for patients who were RPc + ve. Whether the beneficial effect of the presence of receptors on overall survival is the result of a longer disease-free interval or a prolongation of survival after relapse, or both, is not clear, but it is now well established that receptor containing tumours are more likely to respond to endocrine therapy (Maass & Jonat, 1983) , and it has been suggested that the improvement in survival following mastectomy may merely reflect the response to treatment given for recurrent disease (Howat et al., 1982) .
In this study we have sought to establish the role of REc and RPc as prognostic indicators for both recurrence and survival and to relate the results to other factors known to affect the outcome in breast cancer; the involvement of the axillary nodes by tumour and the effect of endocrine therapy following relapse. 
Materials and methods
Receptor assay Oestrogen (REc) and progesterone (RPc) receptors were measured in samples of histologically proven primary tumours from women with breast cancer. The Dextran-coated charcoal assay using [3H] oestradiol or [3H]R5020 a synthetic progestin, has been previously described (Barnes et al., 1977) . Values greater than 5 fmol mg-1 for REc and 15 fmol mg-1 for RPc of cytosol protein were regarded as positive. Negative results from tumours where the cytosol protein was less than 0.7 mg ml-1 were excluded from the study.
Patients
One hundred and seventy five women with operable disease (Tl-3 NO-1MO) were studied. Each had a Patey modified radical mastectomy with a complete dissection of the axilla. Patients with bilateral tumours or distant metastases and those receiving adjuvant endocrine or cytotoxic therapy, were excluded from the study. After histological examination of the axillary nodes, patients were classified into three groups: those with no nodes containing tumour; those with 1-3 nodes containing tumour; and patients with 4 or more nodes containing tumour.
Patients were examined one month after operation, then every six weeks for 2 years, thereafter annually. Local recurrence and nodal disease was confirmed wherever possible by biopsy, while bone or visceral metastases were established on unequivocal radiological evidence.
Upon relapse local recurrence was treated by excision alone or by excision and radiotherapy. Most patients with distant metastases received endocrine treatment, tamoxifen if postmenopausal, a, a.) 
Statistical methods
The steroid receptors were analyzed both as qualitative and quantitative factors. For the study of relapse free survival (RFS), overall survival and post-relapse survival (PRS), time based curves were computed by actuarial methods and compared by the log-rank test (Peto et al., 1977) . Comparison of the different numbers of patients in subgroups was done using the Chi-squared test for contingency tables.
Results
Values for REc and RPc were available from 175 and 163 patients respectively.
Receptor status, node status and relapse-free survival We have previously reported that at 15 months after the last patient entered the study there was a small but statistically significant increase in the RFS of patients with REc compared to those lacking it. This difference was no longer significant when the minimum observation period reached 29 months (Howat et al., 1983) . The most recent analysis was carried out 58 months after the last patient entered the study (maximum follow-up 88 months). Although there was still no statistical difference in the overall RFS of patients with and without REc when examined both qualitatively (P=0.07) and quantitatively (P=0.2) ( Figure IA ), when analysed with respect to menopause or node status both post menopausal patients and those with relatively few involved axillary nodes (1-3) had an improved RFS if their tumours contained The possession of RPc did not increase the RFS during any period of follow-up ( Figure 2A) .
By contrast the presence of tumour invading the axillary nodes had a profound detrimental effect on RFS (P <0.0001). Seventy per cent of node +ve patients had developed recurrent disease within three years compared to 27% of patients whose nodes were uninvolved ( Figure 3A ).
Receptor status, node status and survival after mastectomy Seventy-six patients of whom 22 were premenopausal and 54 postmenopausal developed recurrent disease. Of these 39/76 were REc +ve and 27/70 RPc +ve, ( Table I ). Two of them had no further treatment and 13 had local treatment only.
Of those with disseminiated disease the majority, 89% (53/59) were given endocrine therapy at the time of first relapse regardless of the receptor status of the primary tumour (Table II) . The remainder were given cytotoxic agents only. One patient has been lost to follow-up and one has died of intercurrent illness. Fifty two women have died of breast cancer.
Although there was a lack of any great effect of steroid receptors on the RFS, there were significant differences between patients with and without REc and RPc when survival from mastectomy to death was considered (REc P=0.006 (Figure 3b ). However once relapse had occurred the influence of the node status on survival was no longer apparent and node-ve patients died at the same rate as those who were node+ve (P=0.67) (Figure 3c (Howat et al., 1983) . Data from a more prolonged follow-up of the same patients presented here largely confirms these earlier findings. et Cooke et al., 1980) , whereas others have found that an increase in RFS for RE + ve patients is present only in subgroups based on menopausal and node status (Kinne et al., 1981; Samaan et al., 1981) . In this study an increase was seen in the RFS of REc +ve patients with lymph node involvement. This was most evident in those with minimal disease (1-3 Nodes), suggesting that any beneficial effect of REc on RFS is relatively weak as it is seen neither in those patients with a rapid rate of recurrence after mastectomy (4+nodes) nor in those in whom the recurrence rate is low (node-ve). Hilf et al., 1980; Shapiro et al., 1982; Mason et al., 1983 and Stewart et al., 1983 have found no difference in the RFS of patients with and without REc. Other studies have shown that an initial advantage in favour of REc + ve patients disappears when follow-up exceeds 5 years so that the recurrence rate becomes the same for REc + ve and RE-ve patients (Hiihnel, 1979; Von Maillot et al., 1982; Saez et al., 1983) .
Similarly there is conflicting evidence for a relationship between RPc and RFS. Pichon et al., 1980; Mason et al., 1983, and Saez et al., 1983 , have demonstrated that patients with RPc had a longer disease-free survival than those without. Clark's (1983) study would seem to confirm this although two thirds of his patients had been treated with adjuvant tamoxifen. Others, as in the present study could not show a relationship between RPc and RFS (Allegra et al., 1979; Kinne et al., 1981; Stewart et al., 1983 .) Von Maillot (1982 again found that an early advantage for RPc+ve patients disappeared as follow-up was prolonged.
Why published results are so varied is not clear but it has been shown that the predictive capabilities of a receptor may be altered if the value at which it is deemed positive is redefined (Forrest et al., 1980; Mason et al., 1983) .
There is more general agreement on the relationship between steroid receptors and survival. Most reports have shown that following mastectomy patients with either REc or RPc or both live longer than those who are receptor-ve (Bishop et al., 1979; Hahnel et al., 1979; Kinne et al., 1981; Croton et al., 1981; Godolphin et al., 1981; Stewart et al., 1981; Paterson et al., 1982; Von Maillot et al., 1982; Mason et al., 1983) , although Benson et al., 1982 , reported that an initial increase in overall survival for REc + ve women was no longer apparent after 5 years. Our own results confirm that women with one or both receptors in the primary tumour have a significantly improved survival after mastectomy and that REc + ve RPc + ve patients live longest.
The results of many studies indicate that the REc status of a primary tumour correlates well with the response to any form of endocrine therapy given for recurrent disease. REc +ve patients may show a remission rate of 50-70%, whereas in REc-ve patients the response rate may be as low as 3% (Jensen, 1981; Stewart et al., 1982; Maass & Jonat, 1983) . Most reports of an improved overall survival for REc +ve patients have included women given hormone therapy for advanced disease (Bishop et al., 1979; Hahnel et al., 1979; Stewart et al., 1981; Kinne et al., 1981; Croton et al., 1981; Godolphin et al., 1981; Paterson et al., 1982; Mason et al., 1983) , but in not all of these papers has the effect of receptors after relapse been considered. If it has been discussed, it has been found, as in the present study that REc + ve patients have a significantly longer interval between recurrence and death than do REc-ve patients (Hahnel et al., 1979; Kinne et al., 1981; Paterson et al., 1982 ). This appears to be related to the presence or absence of REc rather than to its level (Stewart et al., 1981) . Godolphin et al., (1981) found the increase in PRS of REc+ve patients to be significant only in those who had received hormones after relapse.
Our results broadly agree with these studies and seem to imply that any increase in survival after mastectomy is chiefly due to the response of receptor+ve patients to endocrine therapy given for recurrent disease rather than to the intrinsic nature of the tumour. Some support for this hypothesis may be derived from our finding that postmenopausal REc + ve and RPc + ve patients have the longest overall survival and postmenopaus4l
RPc + ve patients the longest PRS. Stewart et al. (1983) also found that overall survival was most marked in some receptor + ve postmenopausal patients. This may partly be explained by the observations that absolute values of REc rise with age (Skinner et al., 1980) and that high values of REc are associated with an increased likelihood of a beneficial response to endocrine therapy (McGuire, 1978) . In the present study those patients with highest values of REc survived longest.
As the presence of RPc is closely related to that of REc it might be expected that the results of analysis of the effect of these receptors on survival would be similar. The lack of association between the value of RPc and survival is not readily explained.
The role of RPc in the management of advanced breast cancer is less clearly defined than that of REc but there is increasing evidence that RPc+ve patients also respond more readily to hormones and the response of REc+ve cancers is enhanced by the presence of RPc (McGuire, 1978 , Stewart et al., 1982 Johnson et al., 1983) . In this study PRS was favourably influenced by RPc and again it seems that it is largely the response to treatment of recurrent disease that is reflected in the improved overall survival.
RPc appears to influence PRS to a greater degree than does REc. There were relatively few patients in the study who were REc-ve RPc+ve (12%) compared to those who were REc + ve, RPc-ve (34%) and the majority of RPc+ve patients also had REc (88%). As those with both receptors may be expected to respond more readily to hormone treatment (McGuire, 1978; Stewart et al., 1982) this in time may be reflected by an increase in PRS for RPc+ve patients when compared with those with REc. However, after relapse the incidence of single receptor positivity was similar for both REc and RPc (28% and 22% respectively) and the apparent superiority of RPc may merely result from the relatively small numbers of patients involved.
There is some evidence to suggest that the possession of receptors may influence the overall survival in other ways. We have shown that the RFS of postmenopausal and some node + ve patients was increased if REc was present and Von Maillot (1982) found improved overall survival for both REc and RPc+ve patients in the absence of any endocrine therapy. In addition Stewart et al (1981) and Nicholson and his colleagues (1981) have shown that the site of first distant metastasis can be related to REc status. As the location of metastasis correlates well both to the response to therapy (Baum, 1980) and survival in advanced breast cancer (Cutler, 1969) It has been proposed that as receptor-ve patients fare badly, measurement of receptors may be used to select those women who would benefit from systemic adjuvant therapy following mastectomy (Cooke et al., 1980; Godolphin et al., 1981; Paterson et al., 1982) . As the present study fails to confirm that REc and RPc status can reliably identify patients at risk of early relapse we would doubt this policy, particularly with regard to adjuvant chemotherapy. An accurate knowledge of the axillary node status remains the pre-eminent prognostic factor. The place of routine adjuvant endocrine therapy in the management of operable breast cancer has yet to be established. Preliminary reports suggest that tamoxifen given after mastectomy significantly delays recurrence in some patients (Nolvadex Adjuvant Trial Organisation, 1983; Ribeiro & Palmer, 1983) . Should the efficacy of this form of treatment be confirmed, receptor measurement, whilst failing to predict early relapse in untreated patients may be of some value in identifying those patients most likely to live longer if given adjuvant endocrine therapy (Clark et al., 1983) .
